Product nameAnti-RanBP9 antibody [EPR9920(B)]
See all RanBP9 primary antibodies
DescriptionRabbit monoclonal [EPR9920(B)] to RanBP9
Tested applicationsSuitable for: WB, ICC/IFmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human RanBP9 aa 100-200. The exact sequence is proprietary.
- HeLa, fetal brain and JAR lysates; HeLa cells.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab140627 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 78 kDa.|
|ICC/IF||1/100 - 1/250.|
FunctionMay act as an adapter protein to couple membrane receptors to intracellular signaling pathways. May be involved in signaling of ITGB2/LFA-1 and other integrins. Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway. Involved in activation of androgen and glucocorticoid receptor in the presence of their cognate hormones. Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity. Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA.
Tissue specificityUbiquitously expressed, with highest levels in testes, placenta, heart, and muscle, and lowest levels in lung. Within the brain, expressed predominantly by neurons in the gray matter of cortex, the granular layer of cerebellum and the Purkinje cells.
Sequence similaritiesBelongs to the RANBP9/10 family.
Contains 1 B30.2/SPRY domain.
Contains 1 CTLH domain.
Contains 1 LisH domain.
DomainThe SPRY domain mediates the interaction with MET, AR, and CDC2L1.
modificationsPhosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated in response to stress. Can be phosphorylated by the cleaved p110 form of CDC2L1 (p110C).
Ubiquitinated. Polyubiquitination targets the protein for rapid degradation via the ubiquitin system. Can be deubiquitinated by USP11.
Cellular localizationNucleus. Cytoplasm. A phosphorylated form is associated with the plasma membrane.
- Information by UniProt
- B cell antigen receptor Ig beta associated protein 1 antibody
- BPM 90 antibody
- BPM L antibody
All lanes : Anti-RanBP9 antibody [EPR9920(B)] (ab140627) at 1/1000 dilution
Lane 1 : HeLa cell lysate
Lane 2 : Fetal brain tissue lysate
Lane 3 : JAR cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 78 kDa
Immunofluorescent staining of HeLa cells labelling RanBP9 with ab140627 at 1/100 dilution.